Similar articles

• Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial.

  Szucs TD, Meyer BJ, Kiowski W. Szucs TD, et al. Eur Heart J. 1999 Sep;20(17):1253-60. doi: 10.1053/euhj.1999.1526. Eur Heart J. 1999. PMID: 10454977
• Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease.

  Chesebro JH, Badimon JJ. Chesebro JH, et al. N Engl J Med. 1998 May 21;338(21):1539-41. doi: 10.1056/NEJM199805213382110. N Engl J Med. 1998. PMID: 9593795 No abstract available.
• National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom.

  Bakhai A, Flather MD, Collinson JR, Stevens W, Normand C, Alemao E, Itzler R, Ben-Joseph R. Bakhai A, et al. Int J Cardiol. 2003 Oct;91(2-3):163-72. doi: 10.1016/s0167-5273(03)00023-8. Int J Cardiol. 2003. PMID: 14559126 Clinical Trial.
• Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.

  Fernandez JS, Sadaniantz A. Fernandez JS, et al. Med Health R I. 2001 Feb;84(2):37-43. Med Health R I. 2001. PMID: 11272658 Review. No abstract available.
• Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.

  Plosker GL, Ibbotson T. Plosker GL, et al. Pharmacoeconomics. 2003;21(12):885-912. doi: 10.2165/00019053-200321120-00005. Pharmacoeconomics. 2003. PMID: 12908844 Review.